A scoping review of protein biomarkers for schizophrenia: State of progress, underlying biology, and methodological considerations

Autor(es)

Berdeville, Caio Henrique de Souza Ferreira ; Silva-Amaral, Danyelle ; Dalgalarrondo, Paulo ; Banzato, Claudio E. M. ; Martins-de-Souza, Daniel

• Tipo de documento: Artigo Científico
• Fonte: NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS; v. 168, p. 18-pg., 2025-01-01.

Resumo

Schizophrenia is characterized by symptoms such as delusions, hallucinations, and avolition. The diagnosis is clinical, based on interviews and the main treatment involves antipsychotics. Currently, given the lack of clinically applicable biomarkers for schizophrenia, there is no molecular test based on its biological mechanisms to assist psychiatrists either in the prediction or diagnosis of the disorder, nor to measure medication efficacy. This scoping review assessed original articles in English about protein biomarkers for schizophrenia with samples that could be used in a clinical context, classifying them into diagnosis, prognosis, therapeutics, risk for psychosis, and side-effects. The search was conducted on PubMed and key findings were inserted on a summary table. We discussed the methodologies used in these papers, suggested protein panels for validation in longitudinal research, and proposed a hypothesis to explain the observed variability in results. This heterogeneity is explored in light of the debated validity of this construct, applying recent discussions and the disorder's history. Our data suggest that there is insufficient evidence to integrate protein biomarkers into clinical psychiatry for schizophrenia, not due to study quality, but possibly due to flaws in the current diagnostic system. We propose exploring alternative categorization systems. (AU)

• Processo FAPESP: 23/01211-7 - Ação do canabidiol sobre o metabolismo de glicose e autofagia em astrócitos no contexto da esquizofrenia
• Beneficiário: Danyelle Silva Amaral
• Modalidade de apoio: Bolsas no Brasil - Doutorado
• Processo FAPESP: 24/00735-5 - Caracterização do proteoma intracelular referente ao tratamento combinado de venlafaxina e antipsicóticos atípicos em linhagem de oligodendrócitos imaturos humanos
• Beneficiário: Caio Henrique de Souza Ferreira Berdeville
• Modalidade de apoio: Bolsas no Brasil - Iniciação Científica
• Processo FAPESP: 17/25588-1 - Da compreensão básica a biomarcadores clínicos para a esquizofrenia: um estudo multidisciplinar centrado na neuroproteômica
• Beneficiário: Daniel Martins-de-Souza
• Modalidade de apoio: Auxílio à Pesquisa - Temático
• Processo FAPESP: 22/16373-0 - Investigação das particularidades dos antipsicóticos atípicos a partir do secretoma de oligodendrócitos
• Beneficiário: Caio Henrique de Souza Ferreira Berdeville
• Modalidade de apoio: Bolsas no Brasil - Iniciação Científica